Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems is a promising company in the oncology sector, with a unique drug and device combination product that has shown successful results in treating primary and metastatic liver cancers. With recent improvements in operational efficiencies and better-than-expected financial results, the company is well-positioned for future success. Additionally, potential label expansions and a strong pipeline of indications indicate a bright outlook. However, risks such as competition and pricing could impact the company's success.

Delcath Systems is facing significant challenges in gaining traction for its Melphalan/HDS product, with only 31 active centers and new patient starts per site in Q2 remaining stagnant from Q1. Despite being present in 41% of total NCI-designated centers, the company's referral network is largely inactive. Its reliance on claims data for patient outreach also suggests a lack of strong relationships with doctors, hindering its ability to expand and drive revenue growth.